Elicera Therapeutics
4.42
SEK
-1.89 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-1.89%
+93.86%
+54.55%
+164.67%
+118.81%
+365.26%
+11.19%
-
-28.71%
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
214.53M SEK
Turnover
1.47M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
15/5
2025
General meeting '25
15/5
2025
Interim report Q1'25
29/8
2025
Interim report Q2'25
All
Research
Press releases
3rd party
ShowingAll content types
Elicera Therapeutics: BioStock: Green light to continue Elicera's CARMA-trial in B-cell lymphoma
Carlsquare: Rättelse: Mrkt BUZZ Elicera Therapeutics: Klartecken för att fortsätta CARMA-studien
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools